Pancreatic Cancer Research

ResearcherUniversity of TsukubaActive in the last 2 years

Osamu Shimomura

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0000-0002-1735-5057. Sources: OpenAlex.

Their work

Papers
20 (first author 1, last author 0)
Trials
0
Grants
0
Labs led
0
Collaborators
25
Papers, trials and grants by year

2016: 1 paper · 2017: none · 2018: 1 paper · 2019: none · 2020: 1 paper · 2021: 3 papers · 2022: none · 2023: 5 papers · 2024: 2 papers · 2025: 2 papers · 2026: 5 papers

Papers 20

  1. GlycoChat Uncovers Glycan-Lectin Circuits in the Tumor Microenvironment of Pancreatic Cancer. Co-author DOI 10.1002/advs.202514735↗
  2. Stromal FAP-targeted 18F-FAPI-74 PET/CT in pancreatic ductal adenocarcinoma. Co-author DOI 10.1016/j.pan.2026.07.004↗
  3. Dual-oxygen pancreatic cancer organoids recapitulate basal-classical heterogeneity validated by spatial transcriptomics. Co-author DOI 10.1038/s41416-026-03577-w↗
  4. Prognostic Value of Digitally Quantified CDX2 Expression in Pancreatic Ductal Adenocarcinoma Without Intestinal Differentiation. Co-author DOI 10.1177/10668969261437128↗
  5. Clinical Characteristics and Treatment Courses of Exceptional Long-Term Survivors After Multimodal Therapy Including Proton Beam Therapy for Borderline Resecta… Co-author DOI 10.7759/cureus.115391↗
  6. Identification of CLEC10A as a human lectin for pancreatic ductal adenocarcinoma. Co-author DOI 10.1038/s41598-025-02404-1↗
  7. Safety and pathological impact of resection after high-dose PBT for locally advanced pancreatic cancer. Co-author DOI 10.1186/s12957-025-03992-y↗
  8. Aberrant Glycosylation in Pancreatic Ductal Adenocarcinoma 3D Organoids Is Mediated by KRAS Mutations. Co-author DOI 10.1155/2024/1529449↗
  9. Hypoxia at 3D organoid establishment selects essential subclones within heterogenous pancreatic cancer. Co-author DOI 10.3389/fcell.2024.1327772↗
  10. Lectin-based phototherapy targeting cell surface glycans for pancreatic cancer. Co-author DOI 10.1002/ijc.34362↗
  11. Total Superior Mesenteric Artery Nerve Plexus Preservation During Pancreaticoduodenectomy for Pancreatic Cancer. Co-author DOI 10.1007/s00268-023-07111-4↗
  12. rBC2LCN-reactive SERPINA3 is a glycobiomarker candidate for pancreatic ductal adenocarcinoma. First author DOI 10.1093/glycob/cwad009↗
  13. Novel positron emission tomography imaging targeting cell surface glycans for pancreatic cancer: 18 F-labeled rBC2LCN lectin. Co-author DOI 10.1111/cas.15846↗
  14. Triple modal treatment comprising with proton beam radiation, hyperthermia, and gemcitabine/nab-paclitaxel for locally advanced pancreatic cancer: a phase I/II… Co-author DOI 10.1186/s12885-023-11110-y↗
  15. Quantitative structural analysis of glycans expressed within tumors derived from pancreatic cancer patient-derived xenograft mouse models. Co-author DOI 10.1016/j.bbrc.2020.11.087↗
  16. Survival impact on triple-modal strategy comprising hyperthermia, external radiation, and chemotherapy for unresectable locally advanced (UR-LA) pancreatic duc… Co-author DOI 10.1016/j.suronc.2021.101542↗
  17. Carcinoembryonic antigen as a specific glycoprotein ligand of rBC2LCN lectin on pancreatic ductal adenocarcinoma cells. Co-author DOI 10.1111/cas.15023↗
  18. Novel Pancreatic Cancer Therapy Targeting Cell Surface Glycans by Liposomes Modified with rBC2LCN Lectin. Co-author DOI 10.1159/000513430↗
  19. A Novel Therapeutic Strategy for Pancreatic Cancer: Targeting Cell Surface Glycan Using rBC2LC-N Lectin-Drug Conjugate (LDC). Co-author DOI 10.1158/1535-7163.mct-17-0232↗
  20. Cetuximab delivery and antitumor effects are enhanced by mild hyperthermia in a xenograft mouse model of pancreatic cancer. Co-author DOI 10.1111/cas.12888↗

Closest collaborators

The 25 strongest of 25 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Tatsuya Oda · 19 shared papers, 2016–2026 · strength 3.37
  2. Yoshihiro Miyazaki · 12 shared papers, 2020–2026 · strength 2.10
  3. Hiroaki Tateno · 10 shared papers, 2018–2026 · strength 1.77
  4. Yoshimasa Akashi · 9 shared papers, 2016–2026 · strength 1.48
  5. Hiromitsu Nakahashi · 7 shared papers, 2023–2026 · strength 1.47
  6. Yukihito Kuroda · 6 shared papers, 2020–2026 · strength 1.09
  7. Tomoaki Furuta · 6 shared papers, 2020–2026 · strength 1.00
  8. Koichiro Kumano · 3 shared papers, 2024–2026 · strength 0.72
  9. Hideyuki Sakurai · 4 shared papers, 2021–2026 · strength 0.68
  10. Haruko Numajiri · 4 shared papers, 2021–2026 · strength 0.68
  11. Tsuyoshi Enomoto · 5 shared papers, 2016–2025 · strength 0.68
  12. Masato Endo · 3 shared papers, 2023–2026 · strength 0.61
  13. Kiichiro Tsuchiya · 3 shared papers, 2023–2026 · strength 0.61
  14. Takahito Nakajima · 3 shared papers, 2023–2026 · strength 0.54
  15. Shuntaro Tsukamoto · 2 shared papers, 2025–2026 · strength 0.50
  16. Kentaro Hatano · 2 shared papers, 2023–2026 · strength 0.45
  17. Yusuke Ohara · 3 shared papers, 2016–2023 · strength 0.32
  18. Sota Kimura · 3 shared papers, 2018–2021 · strength 0.30
  19. Yuichi Hiroshima · 2 shared papers, 2021–2025 · strength 0.30
  20. Dinh Xuan Tuan Anh · 1 shared paper, 2026 · strength 0.30
  21. Shuuji Mawaribuchi · 1 shared paper, 2023 · strength 0.19
  22. Kayo Hasehira · 1 shared paper, 2021 · strength 0.16
  23. Nobuhiro Ohkohchi · 2 shared papers, 2016–2018 · strength 0.13
  24. Tomohiro Kurokawa · 1 shared paper, 2016 · strength 0.05
  25. Ryoichi Miyamoto · 1 shared paper, 2016 · strength 0.05

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.